/
GLMD
$0.57-$0.00 (-0.45%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.4M
8M shares
52-week range
$0.41 – $2.34
8% from low
Exchange
NASDAQ
CS
Borrow rate
77.88%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-546.63
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $2.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 100.0% | — | — | — | — | — | — | — |
| R&D | $8.3M | $18.2M | $26.1M | $27.2M | $13.0M | $3.6M | $3.0M | $4.9M |
| Operating income | −$10.7M | −$22.4M | −$30.2M | −$32.9M | −$17.7M | −$7.5M | −$6.3M | −$8.5M |
| EBITDA | −$10.3M | −$22.3M | −$30.2M | −$32.4M | −$17.6M | −$6.9M | −$7.4M | −$10.3M |
| Net income | −$9.9M | −$20.5M | −$28.8M | −$32.5M | −$17.9M | −$6.9M | −$7.5M | −$10.3M |
| Net margin | -483.6% | — | — | — | — | — | — | — |
| EPS (diluted) | -8.15 | -13.17 | -19.46 | -19.48 | -11.08 | -29.95 | -8.08 | -2.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-1.56 | $-1.56–$-1.56 | 1 |
| 2027 | $6M | $-0.90 | $-0.90–$-0.90 | 1 |
| 2028 | $5M | $-0.76 | $-0.76–$-0.76 | 1 |
| 2029 | $17M | $-1.81 | $-1.81–$-1.81 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.51
Price
$0.57
Implied downside
-11%
Peer comparison
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
www.galmedpharma.com- Employees
- 6
- IPO / List date
- Mar 13, 2014
Held by traders on TradeandTell
No one on the platform currently holds GLMD.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GLMD as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-30 | 1-for-12reverse |
| 2023-05-15 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded GLMD yet.
